



September 18, 2025

(Cancellation of Disclosure) Notice of suspension of the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito; hereinafter, the “Company”) hereby announces that, although the Board of Directors resolved to dispose of treasury shares for the Post-delivery Type Performance-linked stock remuneration plan at its meeting held on September 3, 2025, the disposal has been suspended for the reasons detailed below.

Details

1. Reason for suspension of disposal of treasury shares for the Post-delivery Type Performance-linked stock remuneration plan

The Company submitted a Written Notice of Securities to the Kinki Local Finance Bureau on September 3, 2025. However, as the aggregate amount exceeded 100 million yen, the Company has decided to suspend the disposal of treasury shares for the Post-delivery Type Performance-linked stock remuneration plan. On September 18, 2025, the Company also formally requested the withdrawal of its previously submitted Written Notice of Securities.

2. Future plans

The Company will announce details regarding this plan after its Board of Directors finalizes their decisions.

(Reference) Outline of the disposal of treasury shares for the Post-delivery Type Performance-linked stock remuneration plan

The following is an excerpt from “Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan” announced on September 3, 2025.

(1)	Disposal date	September 30, 2025
(2)	Type and number of shares to be disposed of	57,909 shares of the Company's common stock
(3)	Disposal price	1,600.5 yen per share
(4)	Total amount of share disposal	92,683,353 yen
(5)	Recipients of	2 Directors (outside directors excluded): 11,918 shares

allotment of shares to be disposed of, number thereof, and number of shares allotted to be disposed of	4 Corporate officers: 18,529 shares 2 leavers: 27,462 shares
(6) Other	The Company has submitted a Written Notice of Securities for today's Disposal of treasury shares in accordance with the Financial Instruments and Exchange Act.

Contact:

Guillaume Sakuma

Global Head of Investor Relations

E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “*Tenki ni sanyo suru*,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”

For more information, please visit Santen’s website <https://www.santen.com/en>.